



Press release

## GenSight Biologics to Attend Chardan Gene Therapy Conference

**Paris, France, October 4, 2017, 7.30am CET** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the following investor conference:

### **Chardan Inaugural Gene Therapy Conference**

**Tuesday, October 10, 2017 – New York (USA)**

Thomas Gidoïn, Chief Financial Officer, will present on October 10, 2017, at 1:00pm ET, at the Westin New York Grand Central Hotel, and host investor meetings.

### **Contacts**

#### **GenSight Biologics**

Thomas Gidoïn  
Chief Financial Officer  
[tgidoïn@gensight-biologics.com](mailto:tgidoïn@gensight-biologics.com)  
+33 (0)1 76 21 72 20

#### **RooneyPartners**

Media Relations  
Marion Janic  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
+1-212-223-4017

#### **The Trout Group**

Investor Relations  
Chad Rubin  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1-646-378-2947

### **About GenSight Biologics**

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.